Yves HUDE

Actuary / Health Insurance / AI

Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences — Research

Fellow / Postdoctoral Researcher (2022–Present)

• Led AI-driven health risk modeling, resulting in a patented method for personalized health management.

• Conducted deep-dive research into cardiovascular and metabolic diseases and provided

strategic recommendations on tech development and health management solutions.

• Designed feasibility assessments for digital health and medical device projects;

collaborated with clinicians, engineers, and policymakers.

• Evaluated payer-side value frameworks and provided insights for commercialization and regulatory alignment.

• Impact: Delivered insights influencing product development decisions, optimizing risk assessment pathways and evidence generation strategies.

Qianhai Reinsurance Co., Ltd.

—

Healthcare Research (2022–2024)

• Assessed cost-effectiveness and real-world value of emerging drugs and medical devices to support payer and pricing decisions.

• Contributed to health insurance product strategy, integrating clinical evidence and actuarial risk models.

• Conducted technology landscape research and competitive analysis for innovative health solutions

 Impact: Improved underwriting logic and product design for chronic disease management and health insurance products.

INSERM & University of Lyon

—

PhD Researcher (2016–2020)

• Led multiple large-scale RWE projects using French national health insurance (SNDS) database.

• Designed and executed clinical trials evaluating drug/device outcomes.

• Translated complex clinical data into clear insights for academic and industry partners.

• Impact: Published influential research and advised teams on clinical trial design and evidence strategies.

University Hospital of Lyon — Specialist Resident Physician (2014–2016)

• Managed patient care involving stroke, cardiovascular disease, and complex rehabilitation.

• Collaborated with multidisciplinary clinical teams to optimize treatment pathways.

• Impact: Developed deep understanding of disease mechanisms, patient journeys, and real-world treatment decision-making.

 Post Doc, Computer Science and Technology, Chinese Academy of Sciences, China (2022–

2024)

• PhD, Public Health / Biostatistics / Epidemiology, Claude Bernard University Lyon 1, France

(2017–2021)

• MD, Clinical Medicine (Spinal Surgery), Shanghai Jiao Tong University, China (2007–2012)

• Master, Public Health / Pharmacy / Clinical Trials, Claude Bernard University Lyon 1,

France (2012–2013)

• DFMS, Specialist Diploma in Rehabilitation Medicine, University Hospital of Lyon, France

(2016)

• ASA, Associate of the Society of Actuaries, SOA (2021)